Impax Asset Management Group’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $38.9M | Sell |
32,437
-6,882
| -18% | -$7.03M | 0.25% | 76 |
|
|
2026
Q1 | $36.2M | Sell |
39,319
-6,412
| -14% | -$6.5M | 0.25% | 79 |
|
|
2025
Q4 | $49.1M | Sell |
45,731
-13,598
| -23% | -$13M | 0.31% | 74 |
|
|
2025
Q3 | $45.3M | Sell |
59,329
-9,912
| -14% | -$7.38M | 0.26% | 76 |
|
|
2025
Q2 | $54M | Buy |
69,241
+7,803
| +13% | +$6.06M | 0.31% | 80 |
|
|
2025
Q1 | $50.7M | Buy |
61,438
+14,876
| +32% | +$12.4M | 0.31% | 79 |
|
|
2024
Q4 | $35.9M | Buy |
46,562
+25,167
| +118% | +$20.8M | 0.16% | 95 |
|
|
2024
Q3 | $19M | Sell |
21,395
-566
| -3% | -$509K | 0.07% | 131 |
|
|
2024
Q2 | $19.9M | Sell |
21,961
-5,927
| -21% | -$4.74M | 0.08% | 129 |
|
|
2024
Q1 | $21.7M | Sell |
27,888
-2,380
| -8% | -$1.69M | 0.08% | 130 |
|
|
2023
Q4 | $17.6M | Buy |
30,268
+1,560
| +5% | +$911K | 0.07% | 129 |
|
|
2023
Q3 | $15.4M | Sell |
28,708
-2,181
| -7% | -$1.12M | 0.07% | 130 |
|
|
2023
Q2 | $14.5M | Buy |
30,889
+79
| +0.3% | +$33.1K | 0.06% | 139 |
|
|
2023
Q1 | $10.6M | Sell |
30,810
-1,373
| -4% | -$463K | 0.04% | 154 |
|
|
2022
Q4 | $11.8M | Sell |
32,183
-4,089
| -11% | -$1.45M | 0.05% | 151 |
|
|
2022
Q3 | $11.7M | Sell |
36,272
-1,356
| -4% | -$430K | 0.06% | 138 |
|
|
2022
Q2 | $12.2M | Sell |
37,628
-575
| -2% | -$173K | 0.06% | 137 |
|
|
2022
Q1 | $10.9M | Sell |
38,203
-1,609
| -4% | -$414K | 0.05% | 152 |
|
|
2021
Q4 | $11M | Sell |
39,812
-1,463
| -4% | -$371K | 0.04% | 155 |
|
|
2021
Q3 | $9.54M | Buy |
41,275
+75
| +0.2% | +$18.5K | 0.04% | 157 |
|
|
2021
Q2 | $9.46M | Sell |
41,200
-4
| -0% | -$803 | 0.04% | 164 |
|
|
2021
Q1 | $7.7M | Buy |
41,204
+15,089
| +58% | +$2.95M | 0.04% | 165 |
|
|
2020
Q4 | $4.41M | Sell |
26,115
-8,160
| -24% | -$1.22M | 0.03% | 179 |
|
|
2020
Q3 | $5.07M | Buy |
34,275
+11,184
| +48% | +$1.73M | 0.04% | 157 |
|
|
2020
Q2 | $3.79M | Buy |
23,091
+499
| +2% | +$76.6K | 0.04% | 168 |
|
|
2020
Q1 | $3.13M | Buy |
22,592
+3,598
| +19% | +$494K | 0.04% | 164 |
|
|
2019
Q4 | $2.5M | Buy |
18,994
+1,678
| +10% | +$195K | 0.03% | 190 |
|
|
2019
Q3 | $1.94M | Buy |
17,316
+1,424
| +9% | +$159K | 0.03% | 191 |
|
|
2019
Q2 | $1.76M | Buy |
15,892
+416
| +3% | +$49K | 0.02% | 186 |
|
|
2019
Q1 | $2.01M | Sell |
15,476
-143,318
| -90% | -$17.4M | 0.03% | 206 |
|
|
2018
Q4 | $18.4M | Sell |
158,794
-26,721
| -14% | -$2.98M | 0.3% | 67 |
|
|
2018
Q3 | $19.9M | Buy |
+185,515
| New | +$18.5M | 0.29% | 78 |
|
Other funds holding LLY
VCM
VPM
Impax Asset Management Group's LLY Position: Q2 2026 in Review
Impax Asset Management Group reduced its Eli Lilly (LLY) stake by 18% in Q2 2026, selling an estimated $7.03M and leaving 32,437 shares worth $38.9M. The position accounts for 0.25% of the portfolio, ranked #76.
Impax Asset Management Group first reported a position in LLY in Q3 2018 and has held it in 32 quarters since. The position peaked at $54M in Q2 2025. 3,987 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Impax Asset Management Group held 32,437 shares of Eli Lilly worth $38.9M as of Q2 2026.
- Impax Asset Management Group sold 6,882 Eli Lilly shares in Q2 2026, an estimated $7.03M.
- Eli Lilly made up 0.25% of Impax Asset Management Group's portfolio in Q2 2026, its #76 holding.
- Impax Asset Management Group first reported a position in Eli Lilly in Q3 2018 and has held it in 32 quarters since.
- Impax Asset Management Group's Eli Lilly position peaked at $54M in Q2 2025.
- 3,987 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Impax Asset Management Group's 13F filing for Q2 2026, filed 11 Aug 2026.